Prostate Cancer - UK Drug Forecasts and Treatment Analysis to 2020

Prostate Cancer - UK Drug Forecasts and Treatment Analysis to 2020

Summary

GlobalData's pharmaceutical report, “Prostate Cancer - UK Drug Forecasts and Treatment Analysis to 2020” is an essential source of information and analysis on the UK prostate cancer therapeutics market. The report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. It identifies and analyzes the key trends shaping and driving the UK prostate cancer therapeutics market, and analyzes the treatment usage patterns. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global prostate cancer sector. It quantifies the unmet need in the UK prostate cancer therapeutics market, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:
- An overview of prostate cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized UK prostate cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, forecast for 11 years to 2020.
- Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.
- Competitor assessment including drug launch analysis and drug sales forecasts.
- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM (Life Cycle Management) activities and drug sales forecast.
- Analysis of unmet need in the market and target product profiles including opportunity for target products.
- Technology trends analytic framework to assess the strength of the pipeline.
- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, tyrosine kinase inhibitor, angiogenesis inhibitors and others.
- An overview of the most promising drugs including clinical study details, efficacy, safety, collaboration agreements, marketing rights and launch analysis.
- Analysis of the current and future market competition in the UK Prostate Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Sanofi-aventis, Pfizer, Inc., AstraZeneca PLC, Bristol-Myers Squibb, Medivation, Takeda Pharmaceuticals and Dendreon Corporation.
- Analysis of licensing agreements during 2004-2010 in the prostate cancer therapeutics market. Merger and Acquisition (M&A analysis) which includes M&A deals by size and geography.
- Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
- Direct quotes from key opinion leaders (KOL) or physicians in the prostate cancer therapeutics market in the UK.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:
- Develop business strategies and perform superior market quantification analysis by
- Understanding the trends shaping and driving the UK prostate cancer therapeutics market.
- Understanding the treatment preferences of physicians for each disease state and across treatment flow.
- Accessing market sizing forecasts and quantified growth opportunities in the UK prostate cancer therapeutics market up to 2020.
- Quantifying the patient population in the UK to better design product pricing and launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
- Performing benchmarking analysis and growth opportunities against currently marketed products.
- Identifying market entry points based on safety, efficacy, and pricing parameters.
- Assessing competitiveness of products in the market by understanding the strengths and weaknesses of current competition.
- Develop and design your in-licensing and out-licensing strategies by
- Taking a comprehensive look at the disease pipeline and identifying the most promising paradigm-shifting products.
- Assessing the strength of pipeline based on first-in-class, me-too and generic products and their lifecycle management.
- Track drug sales in the UK prostate cancer therapeutics market from 2001 to 2020.
- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
- What’s the next big thing in the UK prostate cancer therapeutics market landscape? Identify, understand and capitalize.

1 Table of contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Disease Overview 10
2.1 Overview 10
2.1.1 TNM (Tumor, Nodes, Metastasis) Staging System 10
2.1.2 Jewett-Whitmore system 11
2.2 Epidemiology 12
2.3 Etiology 12
2.4 Symptoms 12
2.4.1 Localized or Locally Advanced Prostate Cancer 12
2.4.2 Metastatic Prostate Cancer 13
2.5 Diagnosis 13
2.5.1 Digital Rectal Examination 13
2.5.2 Prostate Specific Antigen Test 14
2.5.3 Transrectal Ultrasound 14
2.5.4 Prostate Biopsy 14
2.6 Pathology 15
2.6.1 Grading 15
2.7 Treatment 15
2.7.1 Watchful Waiting 15
2.7.2 Radiation therapy 15
2.7.3 Surgery 16
2.7.4 Hormone therapy 17
2.7.5 Chemotherapy Options 18
2.7.6 Other Treatments Being Studied 18
2.8 Treatment Guidelines 19
3 Market Characterization 20
3.1 The UK 20
3.1.1 Market Size 20
3.1.2 Drivers and Barriers 26
3.1.3 Impact on the Market 27
3.1.4 Forecasts 28
3.1.5 Drug Sales 34
3.1.6 Pricing and Reimbursements 37
4 Competitor Assessment 39
4.1 Strategic Competitor Assessment 39
4.1.1 Overview 39
4.1.2 Benchmarking 39
4.1.3 Current Competitor Assessment 43
4.2 Launch Analysis and Sales Forecasts 44
4.3 Product Profiles 46
4.3.1 Taxotere (docetaxel) 47
4.3.2 Casodex (Bicalutamide) 50
4.3.3 Zoladex (Goserelin) 55
4.3.4 Prostap (leuprolide acetate) 57
4.3.5 Firmagon (degarelix) 58
4.3.6 Novantrone (Mitoxantrone hydrochloride) 60
4.3.7 Emcyt (estramustine) 63
4.3.8 Trelstar (triptorelin) 64
4.3.9 Eulexin 66
4.3.10 Delestrogen 68
4.3.11 Gynodiol 69
4.3.12 Estrace tablet 70
4.3.13 Tace 71
4.3.14 Nilandrone 72
4.3.15 Premarin 73
4.3.16 Sales Forecast for Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol 74
5 Pipeline Assessment 75
5.1 Overview 75
5.2 Pipeline Analysis by Phase of Development 76
5.3 Pipeline by Mechanism of Action 77
5.4 Strategic Pipeline Assessment 78
5.4.1 Technology Trends Analytical Framework 78
5.5 Trends in Prostate Cancer Pipeline 79
5.5.1 More Clarity on the Origin of Prostate Cancer Will Help in Identifying Novel Targets for Prostate Cancer Drugs 79
5.5.2 Molecules with Novel Mechanism of Action Strengthening Prostate Cancer Pipeline 79
5.5.3 Failure of Key Molecules to Achieve Positive Results in Phase III Development 79
5.6 Partners in Research and Development 80
5.6.1 Licensing Agreements by Phase of Development 80
5.6.2 Licensing Agreements by Geography 83
5.6.3 Licensing Agreements: Technology Licensing Agreements in Prostate Cancer 83
5.7 Most Promising Drugs’ Profiles 85
5.7.1 Provenge (sipuleucel-T) 86
5.7.2 Jevtana (cabazitaxel) 88
5.7.3 Aflibercept (VEGF Trap) 90
5.7.4 Ipilimumab 92
5.7.5 Abiraterone Acetate (CB7630) 95
5.7.6 Zibotentan (ZD4054) 97
5.7.7 Sprycel (dasatinib) 99
5.7.8 MDV3100 101
5.8 Prostate Cancer Pipeline – Pre-clinical Phase 104
5.9 Prostate Cancer Pipeline – Phase I 106
5.10 Prostate Cancer Pipeline – Phase II 108
5.11 Prostate Cancer Pipeline – Phase III 115
5.12 Key Takeaway 116
6 Unmet Need and Target Product Profile 117
6.1 Unmet Need 119
6.1.1 Hormone-independent Metastatic Prostate Cancer Therapy 119
6.1.2 Hormone-dependent Metastatic Prostate Cancer Therapy 120
6.2 Opportunity for Target Product 121
6.3 Target Product Profile 122
6.3.1 Ideal Characteristics 122
6.3.2 Target Product Description 123
6.4 Key Takeaway 123
7 Strategic Assessment 124
7.1 Key Events Impacting the Future Market 124
7.2 Market Impact Analysis 125
7.3 Future Market Scenario 125
7.4 Company Analysis 126
7.4.1 Market Leadership 126
7.4.2 Future Players in the Market 127
7.5 Key Takeaway 127
8 Company Profiles 128
8.1 Sanofi-aventis 128
8.1.1 Business Description 128
8.1.2 Financial Overview 130
8.1.3 SWOT Analysis 130
8.1.4 Oncology Focus 135
8.2 Pfizer Inc. 136
8.2.1 Business Description 136
8.2.2 Financial Overview 137
8.2.3 SWOT Analysis 137
8.2.4 Oncology Focus 143
8.3 AstraZeneca 144
8.3.1 Business Description 144
8.3.2 Financial Overview 146
8.3.3 SWOT Analysis 146
8.3.4 Oncology Focus 150
8.4 Bristol-Myers Squibb 152
8.4.1 Business Description 152
8.4.2 Financial Overview 153
8.4.3 SWOT Analysis 153
8.5 Medivation 160
8.5.1 Business Description 160
8.5.2 SWOT Analysis 160
8.5.3 Oncology Focus 163
8.6 Takeda Pharmaceuticals 164
8.6.1 Business Description 164
8.6.2 SWOT Analysis 164
8.7 Dendreon Corporation 165
8.7.1 Business Description 165
8.7.2 SWOT Analysis 166
8.8 Johnson and Johnson 169
8.8.1 Business Description 169
8.8.2 SWOT Analysis 170
8.8.3 Oncology Focus 176
8.9 Auron Healthcare GmbH 177
8.9.1 Business Description 177
8.10 Oncogenex Pharmaceuticals, Inc. 178
8.10.1 Business Description 178
8.11 Agennix AG 178
8.11.1 Business Description 178
8.12 GTx, Inc. 178
8.12.1 Business Description 178
8.13 GlaxoSmithKline plc. 179
8.13.1 Business Description 179
8.13.2 Financial Overview 179
8.13.3 SWOT Analysis 180
8.13.4 Oncology Focus 186
9 M&A Analysis 188
9.1 Key Highlights 188
9.2 Key Deals’ Analysis 189
9.2.1 Johnson & Johnson Acquires Cougar Biotechnology 189
9.2.2 Endo Pharmaceuticals Acquires Indevus Pharmaceuticals 189
9.2.3 Tolmar Holding Acquires QLT USA from QLT 190
9.2.4 Biomarin Pharmaceutical to Acquire Lead therapeutics 190
9.2.5 Isis Pharmaceuticals Reacquires Rights to Cancer Drug from Eli Lilly & Co. 190
9.2.6 Quest PharmaTech Acquires Late-stage Immunotherapeutic Antibody Pipeline from Paladin Labs 190
9.2.7 VaxOnco Acquires Rights to Onyvax-P Cell Vaccine From Onyvax 190
9.2.8 GPC Biotech Merges with Agennix 190
9.2.9 Eli Lilly Acquires ImClone 191
9.2.10 BBM Holdings Acquires YM BioSciences 191
9.2.11 Sagent Pharmaceuticals Acquires Injectable Generic Drug Applications of Spectrum Pharmaceuticals 191
9.3 M&A Deals by Geography 192
9.4 M&A Deals by Deal Size 192
10 Expert Opinion 193
10.1 UK 193
11 Appendix 194
11.1 Market Definitions 194
11.2 Abbreviations 194
11.3 Research Methodology 196
11.3.1 Coverage 196
11.3.2 Secondary Research 197
11.3.3 Forecasting 197
11.3.4 Primary Research 200
11.3.5 Expert Panel validation 200
11.3.6 Contact Us 200
11.3.7 Disclaimer 200
11.3.8 Sources 201